Marker Therapeutics, Inc.
MRKR· Nasdaq
MRKRMarker Therapeutics, Inc.
Released Nov 10, 2022, after the close
10-Q filed Nov 10, 2022, 41 days after period end · 0001410578-22-003131
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $999.57K | — | $0.00 | $0.00 |
| Net Income | -$6.92M | -$12.43M | -$7.37M | -$5.46M |
| EPS Diluted |
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
| -$0.83 |
| -$0.15 |
| -$0.16 |
| -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
